Registre HEAR, Healthcare European Amyloidosis Registry
Saving Lives Matters
5,000 participants
Jun 29, 2021
OBSERVATIONAL
Conditions
Summary
This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up. This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.
Eligibility
Inclusion Criteria10
- Major patient
- Protected adult patient (guardianship or curatorship)
- Prospective Cohort:
- Patients referred or who have been referred to the participating centre for suspected amyloidosis.
- Patient who signed the patient information "Prospective Cohort" note
- Retro-prospective Cohort:
- Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the "retro-prospective cohort" patient information note
- Retrospective cohort:
- Deceased patients followed in the center with a confirmed diagnosis of amyloidosis
- Study participants will not be compensated for their participation
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05101304